Abstract:Background: Alzheimer disease (AD) affects at least 5 million individuals in the USA alone stimulating an intense search for disease prevention and treatment therapies as well as for diagnostic techniques allowing early identification of AD during a long pre-symptomatic period that can be used for the initiation of prevention trials of disease-modifying therapies in asymptomatic individuals.Methods: Our approach to developing such techniques is based on the Gradient Echo Plural Contrast Imaging (GEPCI) technique that provides quantitative in vivo measurements of several brain-tissue-specific characteristics of the gradient echo MRI signal (GEPCI metrics) that depend on the integrity of brain tissue cellular structure.Preliminary data were obtained from 34 participants selected from the studies of aging and dementia at the Knight Alzheimer's Disease Research Center at Washington University in St. Louis. Cognitive status was operationalized with the Clinical Dementia Rating (CDR) scale. The participants, assessed as cognitively normal (CDR=O; n=23) or with mild AD dementia (CDR=0.5 or 1; n=11) underwent GEPCI MRI, a collection of cognitive performance tests and CSF amyloid (A beta) biomarker A beta(42). A subset of 19 participants also underwent PET PiB studies to assess their brain A beta burden. According to the Ap status, cognitively normal participants were divided into normal (A beta negative; n=13) and preclinical (A beta positive; n=10) groups.Results: GEPCI quantitative measurements demonstrated significant differences between all the groups: normal and preclinical, normal and mild AD, and preclinical and mild AD. GEPCI quantitative metrics characterizing tissue cellular integrity in the hippocampus demonstrated much stronger correlations with psychometric tests than the hippocampal atrophy. Importantly, GEPCI-determined changes in the hippocampal tissue cellular integrity were detected even in the hippocampal areas not affected by the atrophy.Our studies also uncovered strong correlations between GEPCI brain tissue metrics and beta-amyloid (A(3) burden defined by positron emission tomography (PET) - the current in vivo gold standard for detection of cortical All, thus supporting GEPCI as a potential surrogate marker for All imaging a known biomarker of early AD. Remarkably, the data show significant correlations not only in the areas of high A beta accumulation (e.g. precuneus) but also in some areas of medial temporal lobe (e.g. parahippocampal cortex), where A beta accumulation is relatively low.Conclusion: We have demonstrated that GEPCI provides a new approach for the in vivo evaluation of AD related tissue pathology in the preclinical and early symptomatic stages of AD. Since MRI is a widely available technology, the GEPCI surrogate markers of AD pathology have a potential for improving the quality of AD diagnostic, and the evaluation of new disease-modifying therapies.

Early Detection of Amyloid Pathology in Alzheimer's Disease by Molecular MRI

[In Vitro Early Detection of Amyloid Plaques in Alzheimer's Disease by Pittsburgh Compound B-modified Magnetic Nanoparticles].

A Novel Magnetic Nanoparticle for Early Detection of Amyloid Plaques in Alzheimer's Disease.

Curcumin-conjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer's disease mice using magnetic resonance imaging (MRI).

Highly Sensitive Curcumin-conjugated Nanotheranostic Platform for Detecting Amyloid-Beta Plaques by Magnetic Resonance Imaging and Reversing Cognitive Deficits of Alzheimer's Disease Via NLRP3-inhibition.

Preparation of Amyloid Immuno-Nanoparticles as Potential MRI Contrast Agents for Alzheimer's Disease Diagnosis.

Evaluation of Dimercaptosuccinic Acid-Coated Iron Nanoparticles Immunotargeted to Amyloid Beta as MRI Contrast Agents for the Diagnosis of Alzheimer's Disease

Preliminary study on early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice using multimodal magnetic resonance imaging

Application of nanotechnology for diagnosis of Alzheimer's disease

Past And Recent Progress Of Molecular Imaging Probes For Beta-Amyloid Plaques In The Brain

Detection of Aβ Plaques by a Novel Specific MRI Probe Precursor CR‐BSA‐(Gd‐DTPA)n in APP/PS1 Transgenic Mice

Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease.

Curcumin Complex Analogues as Near-Infrared Fluorescent Probes for Monitoring all A beta Species in the Early Alzheimer's Disease Model

Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease

Synthesis and evaluation of curcumin-based near-infrared fluorescent probes for detection of amyloid β peptide in Alzheimer mouse models

In Vivo Detection of Microstructural Correlates of Brain Pathology in Preclinical and Early Alzheimer Disease with Magnetic Resonance Imaging.

Fluorescent Peptide Nanoparticles to Detect Amyloid-Beta Aggregation in Cerebrospinal Fluid and Serum for Alzheimer's Disease Diagnosis and Progression Monitoring

Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future

Early Diagnosis of Alzheimer's Disease-Imaging of β-amyloid (A β )Plaques in the Brain with Positron Emission Tomography

Non-invasive optical imaging of retinal Aβ plaques using curcumin loaded polymeric micelles in APP swe /PS1 ΔE9 transgenic mice for the diagnosis of Alzheimer's disease.

Targeted Magnetic Nanoparticles for Beta-Amyloid Detection